

7.6.2021

B9-0306/2021 }
B9-0307/2021 }
B9-0309/2021 }
B9-0311/2021 } RC1/Am. 1

Amendment 1

Geert Bourgeois, Michiel Hoogeveen, Jan Zahradil
on behalf of the ECR Group

Joint motion for a resolution

PPE, S&D, Renew, Verts/ALE

Meeting the global COVID-19 challenge: effects of the waiver of the WTO TRIPS Agreement on COVID-19 vaccines, treatment, equipment and increasing production and manufacturing capacity in developing countries

Joint motion for a resolution

Paragraph 1

Joint motion for a resolution

1. Expresses its strong concern about the development of the pandemic, in particular in low- and middle-income countries; recalls that the COVID-19 pandemic is not yet over and that new vaccines will need to be developed to combat mutations; underlines that the international community must do whatever it takes to get the COVID-19 pandemic under control and that exceptional circumstances require exceptional solutions; stresses therefore that a holistic approach is required, prioritising the availability and affordability of COVID-19 related health products, the scaling-up of COVID-19 vaccine production and the global geographical distribution of manufacturing capacity;

Amendment

1. Expresses its strong concern about the development of the pandemic, in particular in low- and middle-income countries; recalls that the COVID-19 pandemic is not yet over and that new vaccines will need to be developed to combat mutations; underlines that the international community must do whatever it takes to get the COVID-19 pandemic under control and that exceptional circumstances require exceptional solutions; stresses therefore that a holistic approach is required, prioritising the availability and affordability of COVID-19 related health products, the scaling-up of COVID-19 vaccine production and the global geographical distribution of manufacturing capacity; ***expresses scepticism, however, about the usefulness of a TRIPS waiver as the principal solution for equitable access to COVID-19 vaccines worldwide; stresses that patent protection is a key incentive for innovation and research across the globe; underlines that the protection of intellectual property rights was a key driver behind the swift research and incredibly fast and successful***

AM\1233627EN.docx

PE692.580v01-00 }
PE694.416v01-00 }
PE694.418v01-00 }
PE694.420v01-00 } RC1

*development of the range of effective
COVID-19 vaccines available today;*

Or. en

AM\1233627EN.docx

PE692.580v01-00 }
PE694.416v01-00 }
PE694.418v01-00 }
PE694.420v01-00 } RC1

7.6.2021

B9-0306/2021 }
B9-0307/2021 }
B9-0309/2021 }
B9-0311/2021 } RC1/Am. 2

Amendment 2

Geert Bourgeois, Michiel Hoogeveen, Jan Zahradil
on behalf of the ECR Group

Joint motion for a resolution

PPE, S&D, Renew, Verts/ALE

Meeting the global COVID-19 challenge: effects of the waiver of the WTO TRIPS Agreement on COVID-19 vaccines, treatment, equipment and increasing production and manufacturing capacity in developing countries

Joint motion for a resolution

Paragraph 4

Joint motion for a resolution

4. Underlines that, in the long term, global production of vaccines must urgently be expanded to meet global demand, and that investment in the production capabilities of developing countries is therefore needed to make them more self-sufficient; points out the need for effective transfer of technology and know-how to make this happen; recognises that incentivising voluntary licensing agreements and voluntary technology and know-how transfer to countries with pre-existing vaccine-producing industries should be the most important way to achieve this;

Amendment

4. Underlines that, in the long term, global production of vaccines must urgently be expanded to meet global demand, and that investment in the production capabilities of developing countries is therefore needed to make them more self-sufficient; points out the need for effective transfer of technology and know-how to make this happen; recognises that incentivising voluntary licensing agreements and voluntary technology and know-how transfer to countries with pre-existing vaccine-producing industries should be the most important way to achieve this; ***is, however, open to discussing all effective and pragmatic solutions to further boost global vaccine production and calls on the Commission, in particular, to engage with the US and other like-minded countries in this respect; believes, however, that in this context the Commission can only examine specific proposals relating to a time-limited and targeted waiver as a measure of last resort, and only once the broad support of EU Member States for such a targeted, extraordinary and temporary***

AM\1233627EN.docx

PE692.580v01-00 }
PE694.416v01-00 }
PE694.418v01-00 }
PE694.420v01-00 } RC1

measure has been assured;

Or. en

AM\1233627EN.docx

PE692.580v01-00 }
PE694.416v01-00 }
PE694.418v01-00 }
PE694.420v01-00 } RC1

7.6.2021

B9-0306/2021 }
B9-0307/2021 }
B9-0309/2021 }
B9-0311/2021 } RC1/Am. 3

Amendment 3

Geert Bourgeois, Michiel Hoogeveen, Jan Zahradil

on behalf of the ECR Group

Joint motion for a resolution

PPE, S&D, Renew, Verts/ALE

Meeting the global COVID-19 challenge: effects of the waiver of the WTO TRIPS Agreement on COVID-19 vaccines, treatment, equipment and increasing production and manufacturing capacity in developing countries

Joint motion for a resolution

Paragraph 8

Joint motion for a resolution

8. Recognises that trade facilitation and disciplines on export restrictions, the expansion of production, including through pledges by vaccine producers and developers, and the facilitation of TRIPS Agreement flexibilities relating to compulsory licences all play a role in increasing global vaccination; welcomes efforts made by the Director-General of the WTO in bringing members towards a dialogue-based solution; notes the **communications from the European Union to the WTO General Council and TRIPS Council on the urgent trade policy responses to the COVID-19 crisis, which present** three complementary pillars, including trade facilitation and disciplines on export restrictions, and the expansion of production; expects the Commission to increase its engagement to conclude the WTO Trade and Health initiative by the 12th WTO Ministerial Conference in November 2021; calls, furthermore, for the establishment of a Trade and Health Committee at the 12th WTO Ministerial Conference in order to draw lessons from the pandemic, make proposals to increase

AM\1233627EN.docx

Amendment

8. Recognises that trade facilitation and disciplines on export restrictions, the expansion of production, including through pledges by vaccine producers and developers, and the facilitation of TRIPS Agreement flexibilities relating to compulsory licences all play a role in increasing global vaccination; welcomes efforts made by the Director-General of the WTO in bringing members towards a dialogue-based solution; notes the **Commission's intention to present a 'third way' to the WTO proposal in June 2021 focusing on** three complementary pillars, including trade facilitation and disciplines on export restrictions, and the expansion of production; expects the Commission to increase its engagement to conclude the WTO Trade and Health initiative by the 12th WTO Ministerial Conference in November 2021; **notes in this regard the new proposal for an EU Health Initiative**; calls, furthermore, for the establishment of a Trade and Health Committee at the 12th WTO Ministerial Conference in order to draw lessons from the pandemic, make proposals to increase the effectiveness of

PE692.580v01-00 }
PE694.416v01-00 }
PE694.418v01-00 }
PE694.420v01-00 } RC1

the effectiveness of the WTO response during international health crises and to prepare a trade pillar for an international pandemic treaty in order to address supply chain disruption, increase production capacities, take action against price speculation and revisit the WTO law framework in light of lessons learned;

the WTO response during international health crises and to prepare a trade pillar for an international pandemic treaty in order to address supply chain disruption, increase production capacities, take action against price speculation and revisit the WTO law framework in light of lessons learned; ***urges the Commission to ensure, in the event that WTO member states should ultimately decide to make use of the temporary TRIPS waiver, that the quality and safety of the vaccines produced in such non-EU countries is sufficiently high, that there is no increased risk of counterfeiting, and that the free supply of key vaccine ingredients to vaccine manufacturers within the EU can always be guaranteed;***

Or. en